Summary
Bjorn Millard is a computational pharmacology founder and scientist with 16 years of experience building predictive QSP and mechanistic PK/PD models to guide first-in-human dosing, regimen optimization, MoA and toxicity analyses for pharmaceutical clients. As Co‑Founder of Residual Dynamics he combines hands-on model development with project leadership, translating complex simulation and large-scale biomarker analyses into actionable strategies for Phase 1/2 programs. His background spans academic systems biology (PhD, Harvard) and industry roles where he repeatedly delivered on-time, client-facing results that bridge quantitative modeling and experimental design. Notably, he has applied distributed computing and custom analysis software to simulate multi-cellular signaling, bringing rare depth in scalable mechanistic simulation to drug development.
16 years of coding experience
13 years of employment as a software developer
B.S, Neurobiology, B.S, Neurobiology at University of Washington
Ph.D, Systems Biology, Ph.D, Systems Biology at Harvard University